- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02445924
Micro RNA Genetic Signature in NSCLC Egyptian Patients
Micro RNA Genetic Signature in Non-small Cell Lung Cancer Egyptian Patients
This study will be carried out on 40 subjects at Chest department Tanta university hospital
The subjects will be classified into three groups:
- Group I: will include ten non smoker volunteers (control group I).
- GroupII: will include ten smoker volunteers (control groupII).
- Group III: will include twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The patients and control groups will be subjected to the following:
- Complete history taking and complete general examination.
- Complete chest examination.
- Radiological assessment including chest x ray (posteroanterior and lateral view).
- Computed tomography (CT) chest for all patients in group III and when needed in group I and II.
Laboratory investigations:
- Complete blood picture
- Fasting and post parandial blood sugar level
- liver function tests
- kidney function tests (urea and creatinine).
- Prothrombine time and activity.
- Zeil-Neelsen staining of sputum.
- Tumour markers including α Fetoprotein, Carcino Embryonic antigen (CEA), CA19-9, CA 125, CA15-3 and others.
- Venous blood samples will be collected from peripheral blood (5 ml) under complete aseptic technique. Serum samples will be obtained by centrifugation. Isolation of total RNA from serum pools will be performed. RNA profiles and quantification will be assessed using Microarray.
- Lung biopsy either transbronchial via bronchoscopy or peripherally via ultrasound , CT guided, thoracoscopy or open lung biopsy will be performed with isolation of total RNA from lung tissue biopsy. RNA profiles and quantification will be assessed using Microarray.
- Bronchoalveolar lavage will be performed with isolation of total RNA from it. RNA profiles will be assessed using Microarray.
Ethical considerations:
Informed consent will be taken from all subject's and include:
A. The aim of research. B. All data are confidential. C. All data will be used in research only.
For patient's privacy:
A. There will be a code number for each patient in special folder. B. The results of research will be used in scientific publishing only.
- Unexpected risks that appear during the courses of research will be cleared to the participants and the ethical committee on time.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Gharbia
-
Tanta, Gharbia, Egypte, 31111
- Chest Department, Faculty of Medicine, Tanta University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
This study will be carried out on 40 subjects at Chest department Tanta university hospital.
The subjects will be classified into three groups:
- Group I: will include ten non smoker volunteers (control group I).
- GroupII: will include ten smoker volunteers (control groupII).
- Group III: will include twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy.
La description
Inclusion Criteria:
- Inclusion criteria for patients:
Non small cell lung cancer patients recently diagnosed who did not receive chemotherapy, surgery or radiation therapy.
-
Exclusion Criteria:
- Exclusion criteria for patients:
- Diagnosis of asthma or COPD.
- Broncheiactasis.
- upper/lower respiratory tract infection in the preceding 4 weeks.
- Active pulmonary tuberculosis.
- Associated cancer beside lung cancer.
- Patients who received chemotherapy, surgery or radiation therapy previous to the sample collection.
Exclusion criteria for control subjects:
- Diagnosis of asthma or COPD.
- Broncheiactasis.
- Upper/lower respiratory tract infection in the preceding 4 weeks.
- Active pulmonary tuberculosis
- Smoking in group I.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Control group 1
ten non smoker volunteers
|
|
Control group 2
ten smoker volunteers
|
|
NSCLC patients
twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Detect micro RNA genetic signature pattern in non-small cell lung cancer Egyptian patients assessed using Microarray
Délai: one year
|
one year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Abdel-Aziz A Zidan, PHD, Director of Genomics and Proteomics Unit, Center of Excellence in Cancer Research, Tanta University
- Chaise d'étude: Amgad A Farahat, MD, Chest Department, Faculty of Medicine, Tanta University
- Chercheur principal: Ayman H Abd El-Zaher, MD, Chest Department, Faculty of Medicine, Tanta University
- Chercheur principal: Said M Hammad, MD, Clinical Pathology Department, Faculty of Medicine, Tanta University
- Chercheur principal: Adel S Bediwy, MD, Chest Department, Faculty of Medicine, Tanta University
- Chercheur principal: Ayman A Al Saka, MD, Pathology Department, Faculty of Medicine, Tanta University
- Chercheur principal: Samar A Mansour, Master, Chest Department, Faculty of Medicine, Tanta University
Publications et liens utiles
Publications générales
- Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013 Nov;22(6):540-8. doi: 10.1097/CEJ.0b013e32835f3be9.
- Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009 Oct 6;9:353. doi: 10.1186/1471-2407-9-353.
- Leidinger P, Keller A, Meese E. MicroRNAs - Important Molecules in Lung Cancer Research. Front Genet. 2012 Jan 23;2:104. doi: 10.3389/fgene.2011.00104. eCollection 2011.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2858/11/14
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du poumon non à petites cellules
-
Taichung Veterans General HospitalComplétéCardiotoxicité | Cancer du poumon non à petites cellules (MeSH Term: Carcinoma, Non-Small-Cell Lung) | Effets secondaires liés aux médicaments et réactions indésirables (Terme MeSH) | Inhibiteur de la tyrosine kinase d'EGFRTaïwan
-
Fondazione del Piemonte per l'OncologiaRecrutementCancer du sein | Cancer des ovaires | Cancer colorectal | Mélanome (cancer de la peau) | Cancer du poumon non à petites cellules (MeSH Term: Carcinoma, Non-Small-Cell Lung)Italie
-
University of Alabama at BirminghamRésiliéLymphome anaplasique à grandes cellules | Lymphome T angio-immunoblastique | Lymphomes T périphériques | Leucémie à cellules T de l'adulte | Lymphome T adulte | Lymphome T périphérique Non précisé | T/Null Cell Systemic Type | Lymphome cutané à cellules T avec maladie nodale/viscéraleÉtats-Unis
-
Lakefront Biotherapeutics NVActif, ne recrute pasLymphome non hodgkinien à cellules B récidivant/réfractaire | Lymphomes non-hodgkin & amp; amp; # 39; s cell bÉtats-Unis, Belgique, Pays-Bas, Finlande
-
Adelphi Values LLCBlueprint Medicines CorporationComplétéLeucémie mastocytaire (MCL) | Mastocytose systémique agressive (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Mastocytose systémique fumante (SSM) | Mastocytose systémique indolente (ISM) Sous-groupe ISM entièrement recrutéÉtats-Unis
-
National Cancer Institute (NCI)ComplétéCarcinome différencié de la glande thyroïde réfractaire | Carcinome de la glande thyroïde non résécable | Carcinome papillaire de la glande thyroïde réfractaire | Carcinome folliculaire de la glande thyroïde réfractaire | Carcinome réfractaire de la glande thyroïde Hurthle CellÉtats-Unis, Canada